Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma

BACKGROUND: Lung adenocarcinoma (LUAD) is the most common pathological type of lung cancer, with high incidence and mortality. To improve the curative effect and prolong the survival of patients, it is necessary to find new biomarkers to accurately predict the prognosis of patients and explore new s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Cheng, Yang, Hou, Kezuo, Wang, Yizhe, Chen, Yang, Zheng, Xueying, Qi, Jianfei, Yang, Bowen, Tang, Shiying, Han, Xu, Shi, Dongyao, Wang, Ximing, Liu, Yunpeng, Hu, Xuejun, Che, Xiaofang
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264429/
https://ncbi.nlm.nih.gov/pubmed/34249701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.665276
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados